A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development | Citedby Results | Cancer Discovery | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

Cancer Discov (2023) 13 (9): 1982–1997.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma

Anath C. Lionel
Jason Westin

Current Oncology Reports (2023) 25 (11): 1387.

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

Yannick Bulliard
Borje S. Andersson
Mehmet A. Baysal
Jason Damiano
Apostolia M. Tsimberidou

Journal of Hematology & Oncology (2023) 16 (1)

13C tracer analysis reveals the landscape of metabolic checkpoints in human CD8+ T cell differentiation and exhaustion

Alexander Kirchmair
Niloofar Nemati
Giorgia Lamberti
Marcel Trefny
Anne Krogsdam
Anita Siller
Paul Hörtnagl
Petra Schumacher
Sieghart Sopper
Adolf Sandbichler
Alfred Zippelius
Bart Ghesquière
Zlatko Trajanoski

Frontiers in Immunology (2023) 14

Broadening the horizon: potential applications of CAR-T cells beyond current indications

Hendrik Karsten
Ludwig Matrisch
Sophia Cichutek
Walter Fiedler
Winfried Alsdorf
Andreas Block

Frontiers in Immunology (2023) 14

A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy

Kan Wang
Chin-Yuan Tseng
Zhaowei Li
Chip White
Ben Wang
Bruce L. Levine
Andrew D. Fesnak

Cytotherapy (2023) 25 (12): 1370.